Back
GSTP1 (Ile105Val) Gene Polymorphism: Risk and Treatment Response in Chronic Myeloid Leukemia
Shereen Elhoseiny, Mohamed El-Wakil, Mohamed Fawzy, Aya Abdel Rahman
J. Cancer Ther. Vol.5 No.1, December 27, 2013  DOI: 10.4236/jct.2014.51001
       (PDF  432K)     HTML     
Characterization of Genomic Events Other than Ph and Evaluation of Prognostic Influence on Imatinib in Chronic Myeloid Leukemia (CML): A Study on 1449 Patients from India
P. S. Kadam Amare, H. Jain, S. Kabre, D. Walke, H. Menon, M. Sengar, N. Khatri, B. Bagal, U. Dangi, H. Jain, P. G. Subramanian, S. Gujral
J. Cancer Ther. Vol.7 No.4, April 22, 2016  DOI: 10.4236/jct.2016.74030
       (PDF  879K)     HTML      XML
Regional Evaluation of Tolerability and Efficacy of Imatinib Mesylate in Patients with Chronic Phase CML in Mashhad (Iran, Southwest Asia)
Zahra Mozaheb, Maeedeh Javani
Health Vol.6 No.10, April 03, 2014  DOI: 10.4236/health.2014.610113
       (PDF  276K)     HTML     
Analysis of the Capital Asset Pricing Model: Application to General Electric Performance
Issam Tlemsani, Alanoud Alkhaldi, Batool Aljeshi, Israa Alluwaimi, Jawaher Alrayes
Theor. Econ. Lett. Vol.10 No.5, October 26, 2020  DOI: 10.4236/tel.2020.105065
       (PDF  2680K)     HTML      XML
Inhibition of proteasome by bortezomib increase chemosensitivity of bcr/abl positive human k562 chronic myleoid leukemia cells to imatinib
Baran Yusuf, Coskun Oztekin, Bassoy Esen Yonca
Health Vol.1 No.4, December 31, 2009  DOI: 10.4236/health.2009.14052
       (PDF  186K)     HTML     
 
 
Top